Emerging evidence suggests a functional crosstalk between the TGFβ and AXL signaling pathways in hepatocellular carcinoma (HCC) and breast cancer, while their role in CRC has never been addressed before [14, 15]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.